Cancer Survival Rates Higher Than Previously AssumedOctober 09, 2002Conventional estimates for life expectancy after cancer diagnosis have been too pessimistic, suggests a study in this week's issue of THE LANCET. There are two main ways of quantifying survival estimates after cancer diagnosis. The conventional method, known as the cohort method, is based on the survival experience of cancer patients whose diagnosis occurred many years ago. This method therefore fails to disclose recent improvements in cancer detection and treatment. A recently developed alternative survival assessment-called period analysis-provides more up-to-date estimates of cancer survival, as it exclusively uses survival data from a specific time period, such as a particular year. Hermann Brenner from the German Centre for Research on Ageing, Heidelberg, Germany, compared survival estimates obtained with period analysis (for the year 1998) and cohort analysis (for patients diagnosed between 1978 and 1993) using data from the US population based cancer registries. Estimates of 5-year, 10-year, 15-year, and 20-year relative survival rates for all types of cancer were 63%, 57%, 53%, and 51%, respectively, by period analysis. These estimates were 1%, 7%, 11%, and 11% higher, respectively, than corresponding estimates by cohort-based survival analysis. By period analysis, 20-year relative survival rates were close to 90% for thyroid and testicular cancer, exceeded 80% for melanomas and prostate cancer, were about 80% for endometrial cancer, and almost 70% for bladder cancer and Hodgkin's disease. A 20-year relative survival rate of 65% was estimated for breast cancer, of 60% for cervical cancer, and of about 50% for colorectal, ovarian, and kidney cancer. Hermann Brenner comments: "The provision of up-to-date long-term survival rates is not merely an academic exercise-it could help to prevent clinicians and their patients from undue discouragement or depression by outdated and often overly pessimistic survival expectations. Timely detection of improvements in long-term survival rates also adds to the value of cancer surveillance as a basis for appropriate public-health decisions." Contact: Professor Hermann Brenner, Department of Epidemiology,Deutsches Zentrum fur Alternsforschung (DZFA),Bergheimer Strasse 20,D-69115 Heidelberg,Germany;T) +49 6221 54 8140;F)+49 6221 54 8142;E) brenner@dzfa.uni-heidelberg.de Lancet |
|||||||||||||||||||||
| Related Cancer Current Events and Cancer News Articles Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. Does prostate-specific antigen velocity help in early detection prostate cancer? The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection. Key player identified in cascade that leads to hypertension-related kidney damage A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. New Notre Dame study provides insights into the molecular basis of tumor cell behavior A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression. Researcher: 'Optical biopsy' for breast cancer increasingly accurate But women may not have to endure the medical costs, stress and potential complications that accompany such invasive biopsies forever. A University of Florida biomedical engineering researcher is making progress on an "optical biopsy" that has the potential to determine whether growths are cancerous without ever puncturing the skin. Plastic surgeons offer microsurgery technique for breast reconstruction, tummy tuck after mastectomy Since her teens, Jennifer Jablon had watched family members deal with breast cancer during their 40s, 50s, and 60s. She wondered whether it would be her fate too. Newly revised guidelines for managing thyroid cancer published in Thyroid journal The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Magnetic nanoparticles to simultaneously diagnose, monitor and treat Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||